Carfilzomib

FDA Approved: * March 16, 2020
Pharm Company: * APOTEX INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Carfilzomib Overview

Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.[2] It was developed by Onyx Pharmaceuticals. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012, for use in people with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as le...

Read more Carfilzomib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Carfilzomib

Recent Carfilzomib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Carfilzomib
  • Injection: 60mg
  • Powder: 10mg/vial, 30mg/vial, 60mg/vial
  • Unknown: Unknown
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Carfilzomib or a similar ingredient: (1 result)